We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+9.63%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$59.8B
AUM Growth
+$5.07B
(+9.3%)
Cap. Flow
+$518M
Cap. Flow
% of AUM
0.87%
Top 10 Holdings %
Top 10 Hldgs %
18.08%
Holding
2,992
New
38
Increased
2,357
Reduced
537
Closed
43
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$68M |
| 2 |
Truist Financial
TFC
|
+$55.9M |
| 3 |
ServiceNow
NOW
|
+$33.3M |
| 4 |
Uber
UBER
|
+$21.4M |
| 5 |
Las Vegas Sands
LVS
|
+$15.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$119M |
| 2 |
STI
SunTrust Banks, Inc.
STI
|
+$55.9M |
| 3 |
Apple
AAPL
|
+$48.3M |
| 4 |
iShares TIPS Bond ETF
TIP
|
+$22M |
| 5 |
VIAB
Viacom Inc. Class B
VIAB
|
+$16.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Financials | 15.53% |
| 3 | Healthcare | 13.38% |
| 4 | Consumer Discretionary | 10.07% |
| 5 | Industrials | 9.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CWEN.A
2051
DELISTED
Clearway Energy Class A
CWEN.A
| $1.06M | ﹤0.01% |
55,478
+445
| +0.8% | +$8.2K |
|
2052
Vericel Corp
VCEL
$2.28B
| $1.06M | ﹤0.01% |
60,882
+1,245
| +2% | +$21.2K |
|
2053
iShares Russell Mid-Cap ETF
IWR
$57B
| $1.06M | ﹤0.01% |
17,743
-2,007
| -10% | -$115K |
|
2054
Arlo Technologies
ARLO
$1.72B
| $1.05M | ﹤0.01% |
250,553
+13,890
| +6% | +$47.7K |
|
2055
Ecovyst
ECVT
$1.22B
| $1.05M | ﹤0.01% |
61,311
+615
| +1% | +$9.86K |
|
|
TCDA
2056
DELISTED
Tricida, Inc. Common Stock
TCDA
| $1.05M | ﹤0.01% |
27,889
+602
| +2% | +$22.4K |
|
|
APTS
2057
DELISTED
Preferred Apartment Communities, Inc.
APTS
| $1.05M | ﹤0.01% |
78,714
+4,624
| +6% | +$63.8K |
|
|
ATRS
2058
DELISTED
Antares Pharma, Inc.
ATRS
| $1.05M | ﹤0.01% |
222,750
+9,304
| +4% | +$38.1K |
|
2059
El Pollo Loco
LOCO
$506M
| $1.04M | ﹤0.01% |
69,031
+793
| +1% | +$11.1K |
|
|
NE
2060
DELISTED
Noble Corporation
NE
| $1.04M | ﹤0.01% |
856,571
+47,986
| +6% | +$57.4K |
|
2061
Bladex Inc
BLX
$2.19B
| $1.04M | ﹤0.01% |
48,836
+489
| +1% | +$10.3K |
|
2062
Arvinas
ARVN
$556M
| $1.04M | ﹤0.01% |
25,287
+6,496
| +35% | +$190K |
|
2063
HCI Group
HCI
$2.27B
| $1.04M | ﹤0.01% |
22,715
+839
| +4% | +$37K |
|
2064
Midland States Bancorp
MSBI
$714M
| $1.04M | ﹤0.01% |
35,822
+2,013
| +6% | +$55.4K |
|
2065
Pacific Biosciences
PACB
$360M
| $1.04M | ﹤0.01% |
201,480
+3,203
| +2% | +$16.3K |
|
|
XENT
2066
DELISTED
Intersect ENT, Inc
XENT
| $1.03M | ﹤0.01% |
41,580
+388
| +0.9% | +$7.86K |
|
2067
Upland Software
UPLD
$13.4M
| $1.03M | ﹤0.01% |
2,896
+153
| +6% | +$57.2K |
|
|
KBAL
2068
DELISTED
Kimball International
KBAL
| $1.03M | ﹤0.01% |
49,810
+545
| +1% | +$11.2K |
|
|
IVC
2069
DELISTED
Invacare Corporation
IVC
| $1.03M | ﹤0.01% |
114,182
+4,403
| +4% | +$37K |
|
2070
Evolent Health
EVH
$409M
| $1.03M | ﹤0.01% |
113,332
+3,150
| +3% | +$25.6K |
|
2071
Hyster-Yale Materials Handling
HY
$707M
| $1.02M | ﹤0.01% |
17,371
+180
| +1% | +$10K |
|
2072
The Bancorp
TBBK
$3B
| $1.02M | ﹤0.01% |
78,856
+744
| +1% | +$8.34K |
|
|
FLXN
2073
DELISTED
Flexion Therapeutics, Inc.
FLXN
| $1.02M | ﹤0.01% |
49,312
+1,653
| +3% | +$27.9K |
|
|
FTSV
2074
DELISTED
Forty Seven, Inc. Common Stock
FTSV
| $1.02M | ﹤0.01% |
25,891
+4,264
| +20% | +$68.5K |
|
|
VRS
2075
DELISTED
Verso Corporation
VRS
| $1.02M | ﹤0.01% |
56,410
+806
| +1% | +$12.9K |
|
Similar funds
VAM
RhumbLine Advisers's Q4 2019 Portfolio in Review
As of Q4 2019, RhumbLine Advisers held 2,992 positions worth $59.8B, up 9.3% from $54.7B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Trading was light in Q4 2019: portfolio turnover was 2.7%. RhumbLine Advisers opened 38 new positions and exited 43, leaving the 2,992-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q4 2019 buy was Envista: 126,664 shares worth $3.75M.
- RhumbLine Advisers added most to Bristol-Myers Squibb in Q4 2019, an estimated $68M increase.
- RhumbLine Advisers's biggest Q4 2019 reduction was Apple, cutting an estimated $48.3M.
- RhumbLine Advisers fully exited Celgene Corp in Q4 2019, selling an estimated $119M.
- RhumbLine Advisers's ten largest holdings make up 18% of its $59.8B portfolio in Q4 2019.
- RhumbLine Advisers opened 38 new positions and closed 43 in Q4 2019.
- RhumbLine Advisers's portfolio value rose 9.3% quarter-over-quarter to $59.8B.
Based on RhumbLine Advisers's 13F filing for Q4 2019, filed 5 Feb 2020.